Active — Not RecruitingNot Applicable

Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

France274 participantsStarted 2021-05-12

Plain-language summary

This is an observational multicenter study. A cross-sectional descriptive study of patients with locally advanced or metastatic Non Small Cell Lung Cancer with activating EGFR mutation treated by any first line therapy will be used to identify cohort with a prospective follow-up of patients initiating a treatment by osimertinib in first line * A cross-sectional descriptive study of all patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated by any first line therapy will be collected at the study participating sites. The study which is transversal will allow to characterize the population of patients with locally advanced or metastatic NSCLC with activating EGFR mutation treated in first line, the day of first line initiation. * Additionally, a prospective study targeting a cohort of patients focusing on patients with locally advanced or metastatic NSCLC with activating EGFR mutation initiating a treatment by osimertinib in first line will be conducted to address describe in real life conditions the 36-months overall survival, patients baseline characteristics, disease evolution, sequencing and treatment patterns, and quality of life

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Descriptive cross-sectional survey (Population B) * Adult patients (≥ 18 years old), * Patients newly treated in first line (1L) for locally advanced or metastatic NSCLC, * Patients with activating EGFR mutation-positive, * Patient informed and not opposed to these data collection. * Prospective cohort (Population A) * Patient meeting part B inclusion criteria, * Patients newly treated in 1L by osimertinib, * Patient with common EGFR mutation-positive (exon 19 deletion or L858R mutation, alone or co-occuring with other EGFR mutations). Exclusion Criteria (Population A): * Patients enrolled in interventional clinical trials (first line treatment for a NSCLC) during the study period.

What they're measuring

Overall survival

Timeframe: 36 months

Trial details

NCT IDNCT05103605

SponsorAstraZeneca

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-01-15